JPH05320036A - Composition for eliminating singlet oxygen - Google Patents
Composition for eliminating singlet oxygenInfo
- Publication number
- JPH05320036A JPH05320036A JP15001192A JP15001192A JPH05320036A JP H05320036 A JPH05320036 A JP H05320036A JP 15001192 A JP15001192 A JP 15001192A JP 15001192 A JP15001192 A JP 15001192A JP H05320036 A JPH05320036 A JP H05320036A
- Authority
- JP
- Japan
- Prior art keywords
- singlet oxygen
- composition
- skin
- tocopherol
- carotene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 title claims abstract description 42
- 239000000203 mixture Substances 0.000 title claims abstract description 27
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 11
- 235000006708 antioxidants Nutrition 0.000 claims abstract description 11
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims abstract description 11
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 9
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims abstract description 8
- 235000013734 beta-carotene Nutrition 0.000 claims abstract description 8
- 239000011648 beta-carotene Substances 0.000 claims abstract description 8
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims abstract description 8
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims abstract description 8
- GSNUFIFRDBKVIE-UHFFFAOYSA-N 2,5-dimethylfuran Chemical compound CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 claims abstract description 6
- VQKFNUFAXTZWDK-UHFFFAOYSA-N 2-Methylfuran Chemical compound CC1=CC=CO1 VQKFNUFAXTZWDK-UHFFFAOYSA-N 0.000 claims abstract description 6
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 claims abstract description 6
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims abstract description 5
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims abstract description 5
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 claims abstract description 5
- 235000004279 alanine Nutrition 0.000 claims abstract description 5
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims abstract description 5
- 235000012661 lycopene Nutrition 0.000 claims abstract description 5
- 239000001751 lycopene Substances 0.000 claims abstract description 5
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 claims abstract description 5
- 229960004999 lycopene Drugs 0.000 claims abstract description 5
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 claims abstract description 5
- ANVAOWXLWRTKGA-XHGAXZNDSA-N all-trans-alpha-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1C(C)=CCCC1(C)C ANVAOWXLWRTKGA-XHGAXZNDSA-N 0.000 claims abstract description 4
- DMASLKHVQRHNES-UPOGUZCLSA-N (3R)-beta,beta-caroten-3-ol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C DMASLKHVQRHNES-UPOGUZCLSA-N 0.000 claims abstract description 3
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 claims abstract description 3
- VYIRVAXUEZSDNC-TXDLOWMYSA-N (3R,3'S,5'R)-3,3'-dihydroxy-beta-kappa-caroten-6'-one Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC(=O)[C@]1(C)C[C@@H](O)CC1(C)C VYIRVAXUEZSDNC-TXDLOWMYSA-N 0.000 claims abstract description 3
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 claims abstract description 3
- VUPDHIIPAKIKAB-UHFFFAOYSA-N 2,5-diphenylfuran Chemical compound C=1C=C(C=2C=CC=CC=2)OC=1C1=CC=CC=C1 VUPDHIIPAKIKAB-UHFFFAOYSA-N 0.000 claims abstract description 3
- HRQKOYFGHJYEFS-UHFFFAOYSA-N Beta psi-carotene Chemical compound CC(C)=CCCC(C)=CC=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C HRQKOYFGHJYEFS-UHFFFAOYSA-N 0.000 claims abstract description 3
- VYIRVAXUEZSDNC-LOFNIBRQSA-N Capsanthyn Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC(=O)C2(C)CC(O)CC2(C)C VYIRVAXUEZSDNC-LOFNIBRQSA-N 0.000 claims abstract description 3
- 239000004212 Cryptoxanthin Substances 0.000 claims abstract description 3
- GYZWNQLEQAGWGD-DKLMTRRASA-N Isozeaxanthin Chemical compound CC=1C(O)CCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C(O)CCC1(C)C GYZWNQLEQAGWGD-DKLMTRRASA-N 0.000 claims abstract description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims abstract description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims abstract description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims abstract description 3
- 239000004216 Rhodoxanthin Substances 0.000 claims abstract description 3
- VWXMLZQUDPCJPL-ZDHAIZATSA-N Rhodoxanthin Chemical compound CC\1=CC(=O)CC(C)(C)C/1=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C1\C(C)=CC(=O)CC1(C)C VWXMLZQUDPCJPL-ZDHAIZATSA-N 0.000 claims abstract description 3
- VWXMLZQUDPCJPL-XPZLFLLQSA-N Rhodoxanthin Natural products O=C1C=C(C)/C(=C\C=C(/C=C/C=C(\C=C\C=C\C(=C/C=C/C(=C\C=C\2/C(C)=CC(=O)CC/2(C)C)/C)\C)/C)\C)/C(C)(C)C1 VWXMLZQUDPCJPL-XPZLFLLQSA-N 0.000 claims abstract description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims abstract description 3
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 claims abstract description 3
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 claims abstract description 3
- GYZWNQLEQAGWGD-LOFNIBRQSA-N all-trans-Isozeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)C(O)CCC1(C)C)C=CC=C(/C)C=CC2=C(C)C(O)CCC2(C)C GYZWNQLEQAGWGD-LOFNIBRQSA-N 0.000 claims abstract description 3
- VWXMLZQUDPCJPL-JCFHCUBBSA-N all-trans-Rhodoxanthin Natural products CC(=C/C=C/C(=C/C=C/1C(=CC(=O)CC1(C)C)C)/C)C=CC=CC(=CC=CC(=CC=C2/C(=CC(=O)CC2(C)C)C)C)C VWXMLZQUDPCJPL-JCFHCUBBSA-N 0.000 claims abstract description 3
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 claims abstract description 3
- 239000011795 alpha-carotene Substances 0.000 claims abstract description 3
- 235000003903 alpha-carotene Nutrition 0.000 claims abstract description 3
- ANVAOWXLWRTKGA-HLLMEWEMSA-N alpha-carotene Natural products C(=C\C=C\C=C(/C=C/C=C(\C=C\C=1C(C)(C)CCCC=1C)/C)\C)(\C=C\C=C(/C=C/[C@H]1C(C)=CCCC1(C)C)\C)/C ANVAOWXLWRTKGA-HLLMEWEMSA-N 0.000 claims abstract description 3
- LNTHITQWFMADLM-UHFFFAOYSA-N anhydrous gallic acid Natural products OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 claims abstract description 3
- 235000002360 beta-cryptoxanthin Nutrition 0.000 claims abstract description 3
- DMASLKHVQRHNES-ITUXNECMSA-N beta-cryptoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CCCC2(C)C DMASLKHVQRHNES-ITUXNECMSA-N 0.000 claims abstract description 3
- WRANYHFEXGNSND-LOFNIBRQSA-N capsanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC(=O)C2(C)CCC(O)C2(C)C WRANYHFEXGNSND-LOFNIBRQSA-N 0.000 claims abstract description 3
- 235000018889 capsanthin Nutrition 0.000 claims abstract description 3
- 235000021466 carotenoid Nutrition 0.000 claims abstract description 3
- 150000001747 carotenoids Chemical class 0.000 claims abstract description 3
- 235000019244 cryptoxanthin Nutrition 0.000 claims abstract description 3
- 239000011663 gamma-carotene Substances 0.000 claims abstract description 3
- 235000000633 gamma-carotene Nutrition 0.000 claims abstract description 3
- HRQKOYFGHJYEFS-RZWPOVEWSA-N gamma-carotene Natural products C(=C\C=C\C(=C/C=C/C=C(\C=C\C=C(/C=C/C=1C(C)(C)CCCC=1C)\C)/C)\C)(\C=C\C=C(/CC/C=C(\C)/C)\C)/C HRQKOYFGHJYEFS-RZWPOVEWSA-N 0.000 claims abstract description 3
- 235000010382 gamma-tocopherol Nutrition 0.000 claims abstract description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 3
- 235000012680 lutein Nutrition 0.000 claims abstract description 3
- 239000001656 lutein Substances 0.000 claims abstract description 3
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims abstract description 3
- 229960005375 lutein Drugs 0.000 claims abstract description 3
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 claims abstract description 3
- 229930182817 methionine Natural products 0.000 claims abstract description 3
- 239000001688 paprika extract Substances 0.000 claims abstract description 3
- 235000012658 paprika extract Nutrition 0.000 claims abstract description 3
- 235000019246 rhodoxanthin Nutrition 0.000 claims abstract description 3
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 claims abstract description 3
- 235000010930 zeaxanthin Nutrition 0.000 claims abstract description 3
- 239000001775 zeaxanthin Substances 0.000 claims abstract description 3
- 229940043269 zeaxanthin Drugs 0.000 claims abstract description 3
- 239000002478 γ-tocopherol Substances 0.000 claims abstract description 3
- QUEDXNHFTDJVIY-DQCZWYHMSA-N γ-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-DQCZWYHMSA-N 0.000 claims abstract description 3
- 125000005907 alkyl ester group Chemical group 0.000 claims abstract 2
- 125000003042 alpha-carotene group Chemical group 0.000 claims abstract 2
- 229940123973 Oxygen scavenger Drugs 0.000 claims description 10
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 9
- 239000004322 Butylated hydroxytoluene Substances 0.000 claims description 8
- 229960002747 betacarotene Drugs 0.000 claims description 7
- 230000002000 scavenging effect Effects 0.000 claims description 6
- 229960000984 tocofersolan Drugs 0.000 claims description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- 229940087168 alpha tocopherol Drugs 0.000 claims description 4
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 claims description 4
- 235000004835 α-tocopherol Nutrition 0.000 claims description 4
- 239000002076 α-tocopherol Substances 0.000 claims description 4
- WGVKWNUPNGFDFJ-DQCZWYHMSA-N β-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C WGVKWNUPNGFDFJ-DQCZWYHMSA-N 0.000 claims description 4
- GZIFEOYASATJEH-VHFRWLAGSA-N δ-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-VHFRWLAGSA-N 0.000 claims description 4
- ZKSVYBRJSMBDMV-UHFFFAOYSA-N 1,3-diphenyl-2-benzofuran Chemical compound C1=CC=CC=C1C1=C2C=CC=CC2=C(C=2C=CC=CC=2)O1 ZKSVYBRJSMBDMV-UHFFFAOYSA-N 0.000 claims description 2
- PANKHBYNKQNAHN-JTBLXSOISA-N Crocetin Natural products OC(=O)C(\C)=C/C=C/C(/C)=C\C=C\C=C(\C)/C=C/C=C(/C)C(O)=O PANKHBYNKQNAHN-JTBLXSOISA-N 0.000 claims description 2
- GZIFEOYASATJEH-UHFFFAOYSA-N D-delta tocopherol Natural products OC1=CC(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-UHFFFAOYSA-N 0.000 claims description 2
- 235000010323 ascorbic acid Nutrition 0.000 claims description 2
- 239000011668 ascorbic acid Substances 0.000 claims description 2
- 229960005070 ascorbic acid Drugs 0.000 claims description 2
- 229940066595 beta tocopherol Drugs 0.000 claims description 2
- PANKHBYNKQNAHN-JUMCEFIXSA-N carotenoid dicarboxylic acid Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C(=O)O)C=CC=C(/C)C(=O)O PANKHBYNKQNAHN-JUMCEFIXSA-N 0.000 claims description 2
- PANKHBYNKQNAHN-MQQNZMFNSA-N crocetin Chemical compound OC(=O)C(/C)=C/C=C/C(/C)=C/C=C/C=C(\C)/C=C/C=C(\C)C(O)=O PANKHBYNKQNAHN-MQQNZMFNSA-N 0.000 claims description 2
- 235000010389 delta-tocopherol Nutrition 0.000 claims description 2
- 229930003935 flavonoid Natural products 0.000 claims description 2
- 235000017173 flavonoids Nutrition 0.000 claims description 2
- 150000002215 flavonoids Chemical class 0.000 claims description 2
- 229920001864 tannin Polymers 0.000 claims description 2
- 239000001648 tannin Substances 0.000 claims description 2
- 235000018553 tannin Nutrition 0.000 claims description 2
- 239000011590 β-tocopherol Substances 0.000 claims description 2
- 235000007680 β-tocopherol Nutrition 0.000 claims description 2
- 239000002446 δ-tocopherol Substances 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 11
- -1 gallic acid ester Chemical class 0.000 abstract description 11
- 239000001301 oxygen Substances 0.000 abstract description 11
- 229910052760 oxygen Inorganic materials 0.000 abstract description 11
- 238000005502 peroxidation Methods 0.000 abstract description 8
- 238000006243 chemical reaction Methods 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 3
- 150000002632 lipids Chemical class 0.000 abstract description 3
- 239000003795 chemical substances by application Substances 0.000 abstract description 2
- 238000013329 compounding Methods 0.000 abstract description 2
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- CXPUAWQOXQINEX-UHFFFAOYSA-N 1,4-diazocane Chemical compound C1CCNCCNC1 CXPUAWQOXQINEX-UHFFFAOYSA-N 0.000 abstract 1
- 229940074391 gallic acid Drugs 0.000 abstract 1
- 235000004515 gallic acid Nutrition 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 24
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 239000000126 substance Substances 0.000 description 14
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 12
- 229940031439 squalene Drugs 0.000 description 12
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 12
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 11
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 10
- 239000003921 oil Substances 0.000 description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 210000002374 sebum Anatomy 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical group O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 239000012071 phase Substances 0.000 description 8
- 239000008213 purified water Substances 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 7
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 6
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 6
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 5
- 239000001263 FEMA 3042 Substances 0.000 description 5
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 5
- LRBQNJMCXXYXIU-QWKBTXIPSA-N gallotannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@H]2[C@@H]([C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-QWKBTXIPSA-N 0.000 description 5
- 239000002304 perfume Substances 0.000 description 5
- 235000015523 tannic acid Nutrition 0.000 description 5
- 229940033123 tannic acid Drugs 0.000 description 5
- 229920002258 tannic acid Polymers 0.000 description 5
- 102000019197 Superoxide Dismutase Human genes 0.000 description 4
- 108010012715 Superoxide dismutase Proteins 0.000 description 4
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 229960005150 glycerol Drugs 0.000 description 4
- 239000006210 lotion Substances 0.000 description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 4
- 150000002978 peroxides Chemical class 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 3
- 229940058015 1,3-butylene glycol Drugs 0.000 description 3
- 239000004166 Lanolin Substances 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- 235000013871 bee wax Nutrition 0.000 description 3
- 239000012166 beeswax Substances 0.000 description 3
- 235000019437 butane-1,3-diol Nutrition 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 3
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 3
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 3
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 210000004013 groin Anatomy 0.000 description 3
- 235000014304 histidine Nutrition 0.000 description 3
- 235000019388 lanolin Nutrition 0.000 description 3
- 229940039717 lanolin Drugs 0.000 description 3
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 3
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 3
- 229960002216 methylparaben Drugs 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- 229940055577 oleyl alcohol Drugs 0.000 description 3
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000001651 pyrus cydonia seed extract Substances 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 2
- 238000004435 EPR spectroscopy Methods 0.000 description 2
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 description 2
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 2
- JWUXJYZVKZKLTJ-UHFFFAOYSA-N Triacetonamine Chemical compound CC1(C)CC(=O)CC(C)(C)N1 JWUXJYZVKZKLTJ-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229940082500 cetostearyl alcohol Drugs 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000001570 sorbitan monopalmitate Substances 0.000 description 2
- 235000011071 sorbitan monopalmitate Nutrition 0.000 description 2
- 229940031953 sorbitan monopalmitate Drugs 0.000 description 2
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 2
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 1
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 1
- LSHVYAFMTMFKBA-TZIWHRDSSA-N (-)-epicatechin-3-O-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-TZIWHRDSSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 1
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 1
- LSHVYAFMTMFKBA-UHFFFAOYSA-N ECG Natural products C=1C=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 241000097929 Porphyria Species 0.000 description 1
- 208000010642 Porphyrias Diseases 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 229940092738 beeswax Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 235000012734 epicatechin Nutrition 0.000 description 1
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000005283 ground state Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Landscapes
- Cosmetics (AREA)
Abstract
Description
【0001】[0001]
【産業上の利用分野】本発明は、一重項酸素除去組成物
に関し、更に詳しくは、皮膚で発生する一重項酸素除去
作用を有し、結果的に皮膚成分の過酸化反応を抑制する
物質を含む組成物に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a singlet oxygen scavenging composition, and more particularly to a substance having a singlet oxygen scavenging action generated in the skin and consequently suppressing the peroxidation reaction of skin components. A composition comprising.
【0002】[0002]
【従来の技術およびその課題】皮膚におけるいわゆる活
性酸素の存在の言及や、その活性酸素を除去する組成物
についての提案は従来より数多くなされている(例えば
特開平4−69343号公報)。しかしながら、活性酸
素種としては、スーパーオキシド、OHラジカル、ハイ
ドロパーオキシドより発生するラジカル等を対象とし
た、スーパーオキシドディスムターゼ(SOD)やSO
D様の物質、あるいは連鎖切断型の物質がほとんどであ
り、一重項酸素を対象としたものは提案されていない。2. Description of the Related Art There have been many references to the existence of so-called active oxygen in the skin and proposals for a composition for removing the active oxygen (for example, JP-A-4-69343). However, as the reactive oxygen species, superoxide dismutase (SOD) and SO for superoxide, OH radical, radical generated from hydroperoxide, etc. are targeted.
Most of the substances are D-like substances or chain-breaking substances, and no substance for singlet oxygen has been proposed.
【0003】一方、一重項酸素とは基底状態の三重項酸
素(通常の空気中の酸素)より活性化されており、反応
性に富む活性酸素の一種であって、不飽和化合物、例え
ば脂質と反応してハイドロパーオキサイド等、例えば過
酸化脂質を生成する。(二木鋭雄:特集 フリーラジカ
ルの基礎と臨床,日本臨床,46巻,10号,15(2125)〜19
(2129),1988)。ただし、連鎖反応でないので、今まで
は生体内での酸素傷害に対する一重項酸素の寄与はあま
り大きくないと考えられていた。例えば、皮膚と一重項
酸素との関係で言えば、ポルフィリン症はこれが関与し
ていると古くから言われていたが、健康な一般的な皮膚
に関しては、この関与について学術的にも全く触れられ
ていなかった。しかるに本発明者らは、健康なヒト皮膚
において実際に一重項酸素が発生しており、この一重項
酸素が皮膚成分の過酸化反応を進行させることを見い出
し、今までに提案されているような活性酸素除去組成物
では、一重項酸素を含むすべての活性酸素を除去するの
に十分でなく、皮膚外用の組成物として必ずしも満足で
きるものではないことに着目した。On the other hand, singlet oxygen is a type of active oxygen that is activated by ground-state triplet oxygen (normal oxygen in the air) and is highly reactive. The reaction produces hydroperoxide or the like, for example, lipid peroxide. (Tetsuo Niki: Special issue: Basic and clinical studies on free radicals, Japanese clinical practice, 46, No. 10, 15 (2125) ~ 19
(2129), 1988). However, since it is not a chain reaction, it was previously thought that singlet oxygen contributes little to oxygen damage in vivo. For example, when it comes to the relationship between the skin and singlet oxygen, it has long been said that porphyria is involved, but for healthy general skin, there is no academic mention of this involvement. I didn't. However, the present inventors have found that singlet oxygen is actually generated in healthy human skin, and that this singlet oxygen promotes the peroxidation reaction of skin components, and it has been proposed so far. It was noted that the active oxygen removing composition is not sufficient to remove all active oxygen including singlet oxygen, and is not always satisfactory as a composition for external use on the skin.
【0004】しかして本発明は、一重項酸素除去効果剤
を含有せしめることにより、一重項酸素を原因とする皮
膚上における脂質等の過酸化反応を抑制し得る組成物を
提供すること、および連鎖切断型抗酸化剤を併用するこ
とで、皮膚上におけるより多くの活性酸素を原因とする
脂質等の過酸化反応を抑制し得る組成物を提供すること
を目的とする。Therefore, the present invention provides a composition capable of suppressing the peroxidation reaction of lipids and the like on the skin caused by singlet oxygen by containing a singlet oxygen scavenging agent, and a chain It is an object of the present invention to provide a composition capable of suppressing the peroxidation reaction of lipids and the like caused by a larger amount of active oxygen on the skin by using a cleaving antioxidant together.
【0005】[0005]
【課題を解決するための手段】本発明の第1は、一重項
酸素消去剤を含有することを特徴とする一重項酸素除去
組成物である。本発明の第2は、一重項酸素消去剤と、
連鎖切断型抗酸化剤を含有することを特徴とする一重項
酸素除去組成物である。The first aspect of the present invention is a singlet oxygen scavenging composition containing a singlet oxygen scavenger. The second of the present invention is a singlet oxygen scavenger,
A singlet oxygen scavenging composition comprising a chain-breaking antioxidant.
【0006】本発明において、一重項酸素消去剤とは、
一重項酸素と反応してそのエネルギーを失わせるもの、
あるいは一重項酸素との付加物を生じて結果的にそのエ
ネルギーを失わせるもの、あるいはこの両者の作用を有
するものを指す。In the present invention, the singlet oxygen scavenger means
What reacts with singlet oxygen to lose its energy,
Alternatively, it refers to a substance that produces an adduct with singlet oxygen and consequently loses its energy, or a substance that has both of these actions.
【0007】一重項酸素消去剤としては、αカロチン、
βカロチン、γカロチン、リコピン、クリプトキサンチ
ン、ルテイン、ゼアキサンチン、イソゼアキサンチン、
ロドキサンチン、カプサンチン、クロセチン等のカロチ
ノイド、1,4−ジアザジシクロオクタン、2,5−ジ
メチルフラン、2−メチルフラン、2,5−ジフェニル
フラン、1,3−ジフェニルイソベンゾフラン、α−ト
コフェロール、β−トコフェロール、γ−トコフェロー
ル、δ−トコフェロール、ヒスチジン、トリプトファ
ン、メチオニンまたはアラニンが挙げられる。これらの
化合物がよい一重項酸素消去剤であることは、例えば、
八木國夫,中野稔監修:活性酸素,東京,医歯薬出版株
式会社(1987)に記述されている。一重項酸素消去
剤の配合量は0.005〜1重量%が好ましい。As a singlet oxygen scavenger, α-carotene,
β-carotene, γ-carotene, lycopene, cryptoxanthin, lutein, zeaxanthin, isozeaxanthin,
Carotenoids such as rhodoxanthin, capsanthin, and crocetin, 1,4-diazadicyclooctane, 2,5-dimethylfuran, 2-methylfuran, 2,5-diphenylfuran, 1,3-diphenylisobenzofuran, α-tocopherol, Examples include β-tocopherol, γ-tocopherol, δ-tocopherol, histidine, tryptophan, methionine or alanine. That these compounds are good singlet oxygen scavengers include, for example:
Kunio Yagi, Minoru Nakano, supervised by Oxygen, Tokyo, Ito Denryaku Publishing Co., Ltd. (1987). The compounding amount of the singlet oxygen scavenger is preferably 0.005 to 1% by weight.
【0008】次に、連鎖切断型抗酸化剤としては、ジブ
チルヒドロキシトルエン(BHT)、ブチルヒドロキシ
アニソール(BHA)、没食子酸エステル類、アスコル
ビン酸、タンニン酸,エピカテキン,エピガロカテキ
ン,エピカテキンガレート,エピガロカテキンガート等
のタンニン類、ルチン等のフラボノイドが挙げられる。
これらの化合物が効果の高い連鎖切断型抗酸化剤である
ことは、例えば、日本油化学協会編:油化学便覧,丸善
株式会社(1990)に記述されている。連鎖切断型抗
酸化剤の配合量は、0.005〜1重量%が適当であ
る。Next, as chain-breaking antioxidants, dibutylhydroxytoluene (BHT), butylhydroxyanisole (BHA), gallic acid esters, ascorbic acid, tannic acid, epicatechin, epigallocatechin, epicatechin gallate , Tannins such as epigallocatechin gart, and flavonoids such as rutin.
The fact that these compounds are highly effective chain-breaking antioxidants is described in, for example, Japan Oil Chemistry Association: Oil Chemistry Handbook, Maruzen Co., Ltd. (1990). The amount of the chain-breaking antioxidant to be blended is preferably 0.005 to 1% by weight.
【0009】本発明の組成物は、皮膚外用に適用するこ
とが特に好適である。そのような組成物中に添加する他
の添加剤としては、通常の皮膚外用剤の含有成分を添加
することができる。例えば、油分、界面活性剤、増粘
剤、中和剤、防腐剤、粉体成分、色素、金属イオン封鎖
剤、香料、紫外線吸収剤、薬効剤などが挙げられ、必要
に応じて適宜組み合わせて用いられる。The compositions of the invention are particularly suitable for external skin application. As other additives to be added to such a composition, the components contained in ordinary skin external preparations can be added. For example, oils, surfactants, thickeners, neutralizers, preservatives, powder components, dyes, sequestering agents, fragrances, ultraviolet absorbers, medicinal agents, etc. Used.
【0010】[0010]
【作用】健康なヒト皮膚において一重項酸素が重要な影
響を及ぼすことは、本発明者らによる以下のことから確
認された。The effect of singlet oxygen on healthy human skin was confirmed by the present inventors as follows.
【0011】 スクワレンヒドロペルオキシド(ヒト
皮表)の1HNMR測定により一重項酸素反応物を確認 発明者らは、メチレンブルーを増感剤とした精製スクワ
レンの光増感酸化反応により、スクワレンヒドロペルオ
キシドを調製し、そのスペクトルを測定した。1HNM
Rスペクトルによれば、一重項酸素によりスクワレンの
二重結合が攻撃され生成する化合物のプロトンシグナル
を以下の化学式1および2に示すように同定することが
できた。Confirmation of singlet oxygen reactant by 1 HNMR measurement of squalene hydroperoxide (human skin surface) The inventors prepared squalene hydroperoxide by photosensitized oxidation reaction of purified squalene with methylene blue as a sensitizer. Then, the spectrum was measured. 1 HNM
According to the R spectrum, the proton signal of the compound produced by attacking the squalene double bond by singlet oxygen could be identified as shown in the following chemical formulas 1 and 2.
【0012】[0012]
【化1】 [Chemical 1]
【0013】[0013]
【化2】 [Chemical 2]
【0014】発明者らは、そこで太陽光を受けた人ひた
い部より皮脂を収集し、逆相系C18カラムを用いてスク
ワレンヒドロペルオキシド画分を分取した。これを重ク
ロロホルムを溶媒として、1HNMRスペクトルを測定
した。このスペクトルにも同様に1.3ppm(a),
2.7ppm(d)、4.3ppm(3)、5.0pp
m(1)、5.6ppm(c)、7.2ppmおよび
7.8ppm(ヒドロペルオキシル基プロトン)のプロ
トンシグナルが観察された。このことは確かに皮表に一
重項酸素が存在している証拠と考えられる。The inventor collected sebum from the sun sulcus that received sunlight and fractionated the squalene hydroperoxide fraction using a reverse phase C 18 column. Using this as a solvent for deuterated chloroform, 1 H NMR spectrum was measured. This spectrum also has 1.3 ppm (a),
2.7 ppm (d), 4.3 ppm (3), 5.0 pp
Proton signals of m (1), 5.6 ppm (c), 7.2 ppm and 7.8 ppm (hydroperoxyl group protons) were observed. This is considered to be evidence of the presence of singlet oxygen on the skin surface.
【0015】イン・ビトロ・ヒューマン・ファイブロ
ブラスト(in vitro HFB)+UVで一重項酸素の存
在をエレクトロン・パラマグネティック・レゾナンス
(EPR)により確認 発明者らは、全皮膚および表皮をホモジナイズしたも
の、およびヒト線維芽細胞をバッファーに懸濁させたも
のを、実際の皮膚のモデルとした。これらにUVAまた
はUVBを照射した。また一重項酸素のスピン補捉剤と
して、2,2,6,6−テトラメチル−4−ピペリドン
(TMPD)を用い、発生した一重項酸素を捉えて安定
なTMPD−ニトロオキシドの形でEPR定量した。結
果としては、皮膚組織では、UVA照射で顕著に一重項
酸素が発生した。また細胞ホモジナイズ液では、UVB
照射で顕著に一重項酸素が発生した。すなわち実際の皮
膚でも皮膚の内部でも一重項酸素が発生していることが
考えられる。The presence of singlet oxygen was confirmed by electron paramagnetic resonance (EPR) by in vitro human fibroblast (in vitro HFB) + UV. The inventors homogenized whole skin and epidermis, and A suspension of human fibroblasts in a buffer was used as an actual skin model. These were irradiated with UVA or UVB. In addition, 2,2,6,6-tetramethyl-4-piperidone (TMPD) was used as a spin scavenger for singlet oxygen, and the generated singlet oxygen was captured to obtain a stable EPR determination in the form of TMPD-nitrooxide. did. As a result, in the skin tissue, singlet oxygen was remarkably generated by UVA irradiation. In the cell homogenizing solution, UVB
Irradiation significantly generated singlet oxygen. That is, it is considered that singlet oxygen is generated both in the actual skin and inside the skin.
【0016】次に、ヒト皮膚上での一重項酸素が確認さ
れたため、一重項酸素除去組成物である本発明の組成物
が皮膚における過酸化反応を抑制するか否かを次のよう
にして評価した。皮脂過酸化物の低減 実使用テストによるヒト皮膚上での皮脂酸化に対する効
果を以下に示す。Next, since singlet oxygen was confirmed on human skin, whether or not the composition of the present invention, which is a singlet oxygen-scavenging composition, suppresses the peroxidation reaction in the skin was determined as follows. evaluated. Reduction of sebum peroxide The effect on sebum oxidation on human skin by a practical use test is shown below.
【0017】1.試験方法 20歳代から40歳代の健康な男性の被験者5名に以下
に示される処方を配合したローションをひたい部に塗布
し、10分後にひたい部を太陽光に曝し、その後ひたい
部より皮脂を採取し、皮脂中のスクアレンが酸化された
度合いを測定した。1. Test method Five healthy male subjects in their 20s to 40s were applied with lotion containing the formulation shown below to the groin area, 10 minutes later, the groin area was exposed to sunlight, and then sebum was applied from the groin area. Was sampled and the degree of oxidation of squalene in sebum was measured.
【0018】2.実使用テスト使用ローション処方 試料(表1の物質を添加) 0.02% クエン酸 0.01% クエン酸ソーダ 0.1% アルコール未変95% 7.0% ポリオキシエチレン(20モル) オレイルアルコール 0.5% 精製水 残余2. Practical use test Use lotion formulation Sample (add the substances in Table 1) 0.02% Citric acid 0.01% Sodium citrate 0.1% Alcohol unchanged 95% 7.0% Polyoxyethylene (20 mol) Oleyl alcohol 0.5% purified water residue
【0019】結果を表1にまとめた。ここで、スクワレ
ンヒドロペルオキシド生成量は、皮脂中のスクワレン1
モル当たりのスクワレンヒドロペルオキシド量をスクワ
レンヒドロペルオキシド標準品を用いて、CL−HPL
C法で求め、5名の平均値を記した(河野ら、油化学、
40(9)P.715(’91)参照)。The results are summarized in Table 1. Here, the production amount of squalene hydroperoxide is 1 squalene in sebum.
The amount of squalene hydroperoxide per mole was measured using CL-HPL using a squalene hydroperoxide standard.
The average value of 5 people was recorded by the C method (Kono et al., Oil chemistry,
40 (9) P. 715 ('91)).
【0020】[0020]
【表1】 ──────────────────────────────── 試料 スクワレンヒドロ ペルオキシド生成量 ──────────────────────────────── 対照例1 − 4.9×10-3 対照例2 SOD 4.7×10-3 対照例3 BHT 3.2×10-3 本発明例1 β-カロチン 2.3×10-3 本発明例2 ヒスチジン 2.5×10-3 本発明例3 dl−αトコフェロール 1.8×10-3 本発明例4 β-カロチン(0.005%)+BHT(0.005%) 1.9×10-3 本発明例5 β-カロチン(0.01%)+BHT(0.01%) 1.0×10-3 本発明例6 ヒスチジン(0.01%)+BHT(0.01%) 1.4×10-3 ────────────────────────────────[Table 1] ──────────────────────────────── Sample squalene hydroperoxide production ───────── ──────────────────────── Control Example 1 − 4.9 × 10 −3 Control Example 2 SOD 4.7 × 10 −3 Control Example 3 BHT 3.2 × 10 − 3 Inventive Example 1 β-carotene 2.3 × 10 −3 Inventive Example 2 Histidine 2.5 × 10 −3 Inventive Example 3 dl-α tocopherol 1.8 × 10 −3 Inventive Example 4 β-carotene (0.005%) + BHT (0.005) %) 1.9 × 10 -3 Inventive Example 5 β-carotene (0.01%) + BHT (0.01%) 1.0 × 10 -3 Inventive Example 6 Histidine (0.01%) + BHT (0.01%) 1.4 × 10 -3 ─── ─────────────────────────────
【0021】表1からわかるように、本発明による組成
物は、連鎖切断型抗酸化剤を含まない場合(本発明例
1、2)でも、連鎖切断型抗酸化剤単独(対照例3)や
SOD(対照例2)の場合と同等以上のスクワレンヒド
ロペルオキシド生成抑制効果を有しており、皮脂過酸化
物の低減化に有用である。As can be seen from Table 1, even when the composition according to the present invention does not contain the chain-cutting antioxidant (Invention Examples 1 and 2), the chain-cutting antioxidant alone (Control Example 3) or It has a squalene hydroperoxide production inhibitory effect equivalent to or higher than that of SOD (Comparative Example 2), and is useful for reducing sebum peroxide.
【0022】[0022]
【実施例】以下に実施例によって、本発明を更に具体的
に説明するが、本発明はこの実施例に制限されるもので
はない。The present invention will be described in more detail with reference to the following examples, but the present invention is not limited to these examples.
【0023】実施例1(化粧水) アラニン 1.0重量% タンニン酸 0.1 グリセリン 4.0 1,3−ブチレングリコール 4.0 エタノール 7.0 ポリオキシエチレン(20モル) オレイルアルコール 0.5 メチルパラベン 0.05 クエン酸 0.01 クエン酸ソーダ 0.1 香料 0.05 精製水 残余Example 1 (Lotion) Alanine 1.0% by weight Tannic acid 0.1 Glycerin 4.0 1,3-Butylene glycol 4.0 Ethanol 7.0 Polyoxyethylene (20 mol) Oleyl alcohol 0.5 Methylparaben 0.05 Citric acid 0.01 Sodium citrate 0.1 Perfume 0.05 Purified water Residual
【0024】製法 精製水にクエン酸、クエン酸ソーダ、グリセリン、1,
3−ブチレングリコール、アラニンおよびタンニン酸を
溶解する。別にエタノールにポリオキシエチレンオレイ
ルアルコール、香料およびメチルパラベンを溶解し、こ
れを前述の水溶液に加えて可溶化し、濾過して化粧水を
得た。 Manufacturing method Citric acid, sodium citrate, glycerin, 1,
Dissolve 3-butylene glycol, alanine and tannic acid. Separately, polyoxyethylene oleyl alcohol, a fragrance and methylparaben were dissolved in ethanol, and this was added to the above aqueous solution to solubilize it, followed by filtration to obtain a lotion.
【0025】実施例2(クリーム) セトステアリルアルコール 3.5重量% スクワラン 40.0 ミツロウ 3.0 還元ラノリン 5.0 エチルパラベン 0.3 ポリオキシエチレン(20モル) ソルビタンモノパルミチン酸エステル 2.0 ステアリン酸モノグリコシド 2.0 β-カロチン 0.01 BHT 0.01 香料 0.03 1,3−ブチレングリコール 5.0 グリセリン 5.0 ヒアルロン酸ナトリウム 0.05 精製水 残余Example 2 (Cream) Cetostearyl alcohol 3.5% by weight Squalane 40.0 Beeswax 3.0 Reduced lanolin 5.0 Ethylparaben 0.3 Polyoxyethylene (20 mol) Sorbitan monopalmitate 2.0 Stearic acid monoglycoside 2.0 β-carotene 0.01 BHT 0.01 Perfume 0.03 1,3-butylene glycol 5.0 Glycerin 5.0 Sodium hyaluronate 0.05 Purified water Residual
【0026】製法 セトステアリルアルコール、スクワラン、ミツロウ、還
元ラノリン、エチルパラベン、ポリオキシエチレン(2
0モル)ソルビタンモノパルミチン酸エステル、ステア
リン酸モノグリコシド、β−カロチン、BHTおよび香
料を加熱溶解し75℃に保ったものを、75℃に加温し
た1,3−ブチレングリコール、グリセリン、ヒアルロ
ン酸ナトリウムおよび精製水に攪拌しながら加える。ホ
モミキサー処理し乳化粒子を細かくした後、攪拌しなが
ら急冷し、クリームを得た。 Manufacturing method : cetostearyl alcohol, squalane, beeswax, reduced lanolin, ethylparaben, polyoxyethylene (2
(0 mol) sorbitan monopalmitate, stearic acid monoglycoside, β-carotene, BHT and perfume which were heated and melted and kept at 75 ° C were heated to 75 ° C to give 1,3-butylene glycol, glycerin and hyaluronic acid. Add to sodium and purified water with stirring. After homogenizing with a homomixer to make the emulsified particles fine, the mixture was rapidly cooled with stirring to obtain a cream.
【0027】実施例3(乳液) α−トコフェロール 0.02重量% ステアリン酸 1.5 セチルアルコール 0.5 ミツロウ 2.0 ポリオキシエチレン(10モル) モノオレイン酸エステル 1.0 ステアリン酸モノグリコシド 1.0 クインスシード抽出液(5%水溶液) 20.0 プロピレングリコール 5.0 エタノール 3.0 エチルパラベン 0.3 メチルパラベン 0.05 香料 0.05 精製水 残余Example 3 (Emulsion) α-tocopherol 0.02% by weight Stearic acid 1.5 Cetyl alcohol 0.5 Beeswax 2.0 Polyoxyethylene (10 mol) monooleate 1.0 1.0 Stearate monoglycoside 1 0.0 Quinceseed extract (5% aqueous solution) 20.0 Propylene glycol 5.0 Ethanol 3.0 Ethylparaben 0.3 Methylparaben 0.05 Perfume 0.05 Purified water Residual
【0028】製法 エタノールにα−トコフェロール、香料を加えて溶解す
る(アルコール溶液)。精製水にプロピレングリコール
を加え加熱溶解して70℃に保つ(水相)。クインスシ
ード抽出液を除く他の成分を混合し、加熱溶解して70
℃に保つ(油相)。水相に油相を加え予備乳化を行い、
ホモミキサーで均一に乳化する。これを攪拌しながらア
ルコール溶液とクインスシード抽出液を加える。その後
攪拌しながら30℃に急冷して乳液を得た。[ Production Method ] α-tocopherol and a fragrance are added to ethanol and dissolved (alcohol solution). Propylene glycol is added to purified water, dissolved by heating, and maintained at 70 ° C (aqueous phase). Mix other ingredients except quince seed extract, heat and dissolve to 70
Keep at ℃ (oil phase). Add the oil phase to the water phase and pre-emulsify,
Emulsify uniformly with a homomixer. While stirring this, an alcohol solution and a quince seed extract are added. Then, it was rapidly cooled to 30 ° C. with stirring to obtain an emulsion.
【0029】実施例4(ファンデーション) リコピン 0.01重量% タンニン酸 0.01 流動パラフィン 27.0 ラノリン 10.0 固形パラフィン 5.0 ソルビタンセスキオレート 5.0 粉末着色料 35.0 香料 適量 防腐剤 適量 精製水 残余Example 4 (Foundation) Lycopene 0.01% by weight Tannic acid 0.01 Liquid paraffin 27.0 Lanolin 10.0 Solid paraffin 5.0 Sorbitan sesquioleate 5.0 Powder colorant 35.0 Perfume Suitable amount Preservative Suitable amount Purified water Residual
【0030】製法 粉末着色料とソルビタンセスキオレートを混合し、流動
パラフィンの一部を加えて乳化機にて均一な着色料の分
散した油相をつくる。リコピンおよび残部の油相を混合
加熱し、融解してさらに先の油相を添加し、70℃に保
つ。精製水およびタンニン酸を70℃に加熱溶解したも
のを油相に加えた後、強力な乳化機で乳化し、乳化後冷
却しながらかきまぜ、40℃にて容器に充填し、放冷す
る。 Manufacturing method The powder colorant and sorbitan sesquioleate are mixed and a part of liquid paraffin is added to form an oil phase in which the colorant is uniformly dispersed by an emulsifying machine. The lycopene and the rest of the oil phase are mixed and heated, melted and the previous oil phase is added and kept at 70 ° C. After adding purified water and tannic acid dissolved at 70 ° C. to the oil phase, the mixture is emulsified by a powerful emulsifier, stirred after cooling after emulsification, filled in a container at 40 ° C., and allowed to cool.
【0031】[0031]
【発明の効果】以上説明したように、本発明によれば健
康なヒト皮膚表面の過酸化反応を誘起させる原因物質の
一つである一重項酸素を除去する成分を含ませることに
より、過酸化反応の原因物質の一つが取り除かれ、皮脂
過酸化物の低減に寄与する。また、一重項酸素を除去す
る成分と共に連鎖切断型抗酸化剤を併せて配合すること
で他の過酸化反応原因物質も除去され、皮脂過酸化物の
低減化に一層寄与できる。INDUSTRIAL APPLICABILITY As described above, according to the present invention, by adding a component that removes singlet oxygen, which is one of the causative substances that induces the peroxidation reaction on the surface of healthy human skin, One of the causative substances of the reaction is removed, contributing to the reduction of sebum peroxide. In addition, by adding together a chain scission-type antioxidant together with a component for removing singlet oxygen, other substances responsible for the peroxidation reaction are also removed, which can further contribute to the reduction of sebum peroxide.
Claims (4)
とする一重項酸素除去組成物。1. A singlet oxygen scavenging composition comprising a singlet oxygen scavenger.
を含有することを特徴とする一重項酸素除去組成物。2. A singlet oxygen scavenging composition comprising a singlet oxygen scavenger and a chain-breaking antioxidant.
ロチン、γカロチン、リコピン、クリプトキサンチン、
ルテイン、ゼアキサンチン、イソゼアキサンチン、ロド
キサンチン、カプサンチン、クロセチン等のカロチノイ
ド、1,4−ジアザジシクロオクタン、2,5−ジメチ
ルフラン、2−メチルフラン、2,5−ジフェニルフラ
ン、1,3−ジフェニルイソベンゾフラン、α−トコフ
ェロール、β−トコフェロール、γ−トコフェロール、
δ−トコフェロール、ヒスチジン、トリプトファン、メ
チオニン、アラニンまたはそのアルキルエステルである
請求項1または2に記載の一重項酸素除去組成物。3. The singlet oxygen scavenger is α-carotene, β-carotene, γ-carotene, lycopene, cryptoxanthin,
Carotenoids such as lutein, zeaxanthin, isozeaxanthin, rhodoxanthin, capsanthin, crocetin, 1,4-diazadicyclooctane, 2,5-dimethylfuran, 2-methylfuran, 2,5-diphenylfuran, 1,3-diphenyl Isobenzofuran, α-tocopherol, β-tocopherol, γ-tocopherol,
The singlet oxygen-scavenging composition according to claim 1 or 2, which is δ-tocopherol, histidine, tryptophan, methionine, alanine or an alkyl ester thereof.
キシトルエン(BHT)、ブチルヒドロキシアニソール
(BHA)、没食子酸エステル類、アスコルビン酸、タ
ンニン類またはフラボノイドである請求項2記載の一重
項酸素除去組成物。4. The singlet oxygen scavenger according to claim 2, wherein the chain-breaking antioxidant is dibutylhydroxytoluene (BHT), butylhydroxyanisole (BHA), gallic acid esters, ascorbic acid, tannins or flavonoids. Composition.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP15001192A JPH05320036A (en) | 1992-05-19 | 1992-05-19 | Composition for eliminating singlet oxygen |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP15001192A JPH05320036A (en) | 1992-05-19 | 1992-05-19 | Composition for eliminating singlet oxygen |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH05320036A true JPH05320036A (en) | 1993-12-03 |
Family
ID=15487531
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP15001192A Withdrawn JPH05320036A (en) | 1992-05-19 | 1992-05-19 | Composition for eliminating singlet oxygen |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH05320036A (en) |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0959151A (en) * | 1995-08-24 | 1997-03-04 | Kao Corp | Nf-kappa b activation suppressing agent |
EP0761214A2 (en) | 1995-07-21 | 1997-03-12 | Kao Corporation | N,N-disubstituted anilines or alkylamines as singlet oxygen quenchers, topical compositions comprising them |
JPH09175983A (en) * | 1995-12-28 | 1997-07-08 | Kao Corp | Skin preparation for external use |
JPH10195433A (en) * | 1996-12-27 | 1998-07-28 | Nippon Nouken:Kk | Antioxidant |
JPH11193226A (en) * | 1993-12-28 | 1999-07-21 | Kose Corp | Collagen crosslink suppressant |
GB2301775B (en) * | 1995-06-07 | 1999-08-04 | Howard Foundation | Treatment of age-related macular degeneration with carotenoids |
JP2000319159A (en) * | 1999-05-10 | 2000-11-21 | Nonogawa Shoji Kk | Skin preparation for external use |
FR2815864A1 (en) * | 2000-10-26 | 2002-05-03 | Oreal | USE OF THE COMBINATION OF AT LEAST ONE CAROTENOID AND VITAMIN C TO TREAT THE SKIN SIGNS OF AGING |
FR2815861A1 (en) * | 2000-10-26 | 2002-05-03 | Oreal | USE OF THE COMBINATION OF AT LEAST ONE CAROTENOID AND AT LEAST ONE ISOFLAVONOID FOR TREATING SKIN SIGNS OF AGING |
JP2002128651A (en) * | 2000-10-25 | 2002-05-09 | Kose Corp | Photoaging inhibitor and skin care preparation characterized by comprising the same |
JP2003212709A (en) * | 2002-01-22 | 2003-07-30 | Saadonikkusu:Kk | Functional cosmetic composition |
JP2007326829A (en) * | 2006-06-09 | 2007-12-20 | Fujifilm Corp | Emulsion composition |
JP2008100991A (en) * | 2006-09-22 | 2008-05-01 | Rohto Pharmaceut Co Ltd | Aqueous preparation having stabilized carotenoid |
US7452549B2 (en) | 2000-10-24 | 2008-11-18 | Nestec S.A. | Synergistic antioxidant combination of delta tocols and polyphenols |
JP2010235483A (en) * | 2009-03-31 | 2010-10-21 | Kose Corp | Singlet oxygen scavenger and skin external preparation and cosmetic containing the same |
JP2010285364A (en) * | 2009-06-10 | 2010-12-24 | Riken Vitamin Co Ltd | Singlet oxygen scavenger |
WO2011040070A1 (en) * | 2009-09-30 | 2011-04-07 | 株式会社資生堂 | Oral composition for alleviation of ultraviolet radiation-induced damage |
JP2011162493A (en) * | 2010-02-12 | 2011-08-25 | Riken Vitamin Co Ltd | Crocetin composition |
JP2013126965A (en) * | 2011-11-14 | 2013-06-27 | Fujifilm Corp | Nrf2 ACTIVATOR FOR NORMAL SKIN CELL |
US8835497B2 (en) | 2003-07-03 | 2014-09-16 | Hill's Pet Nutrition, Inc. | Compositions for improved oxidative status in companion animals |
-
1992
- 1992-05-19 JP JP15001192A patent/JPH05320036A/en not_active Withdrawn
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11193226A (en) * | 1993-12-28 | 1999-07-21 | Kose Corp | Collagen crosslink suppressant |
GB2301775B (en) * | 1995-06-07 | 1999-08-04 | Howard Foundation | Treatment of age-related macular degeneration with carotenoids |
EP0761214A2 (en) | 1995-07-21 | 1997-03-12 | Kao Corporation | N,N-disubstituted anilines or alkylamines as singlet oxygen quenchers, topical compositions comprising them |
JPH0959151A (en) * | 1995-08-24 | 1997-03-04 | Kao Corp | Nf-kappa b activation suppressing agent |
JPH09175983A (en) * | 1995-12-28 | 1997-07-08 | Kao Corp | Skin preparation for external use |
JPH10195433A (en) * | 1996-12-27 | 1998-07-28 | Nippon Nouken:Kk | Antioxidant |
JP2000319159A (en) * | 1999-05-10 | 2000-11-21 | Nonogawa Shoji Kk | Skin preparation for external use |
US7452549B2 (en) | 2000-10-24 | 2008-11-18 | Nestec S.A. | Synergistic antioxidant combination of delta tocols and polyphenols |
JP2002128651A (en) * | 2000-10-25 | 2002-05-09 | Kose Corp | Photoaging inhibitor and skin care preparation characterized by comprising the same |
WO2002034210A3 (en) * | 2000-10-26 | 2002-06-27 | Oreal | Use of the association of at least a carotenoid and vitamin c for treating cutaneous symptoms of ageing |
WO2002034233A3 (en) * | 2000-10-26 | 2002-08-29 | Oreal | Use of an association of a carotenoid and of an isoflavonoid for treating cutaneous symptoms of ageing |
FR2815861A1 (en) * | 2000-10-26 | 2002-05-03 | Oreal | USE OF THE COMBINATION OF AT LEAST ONE CAROTENOID AND AT LEAST ONE ISOFLAVONOID FOR TREATING SKIN SIGNS OF AGING |
FR2815864A1 (en) * | 2000-10-26 | 2002-05-03 | Oreal | USE OF THE COMBINATION OF AT LEAST ONE CAROTENOID AND VITAMIN C TO TREAT THE SKIN SIGNS OF AGING |
JP2003212709A (en) * | 2002-01-22 | 2003-07-30 | Saadonikkusu:Kk | Functional cosmetic composition |
US8835497B2 (en) | 2003-07-03 | 2014-09-16 | Hill's Pet Nutrition, Inc. | Compositions for improved oxidative status in companion animals |
JP2007326829A (en) * | 2006-06-09 | 2007-12-20 | Fujifilm Corp | Emulsion composition |
JP2008100991A (en) * | 2006-09-22 | 2008-05-01 | Rohto Pharmaceut Co Ltd | Aqueous preparation having stabilized carotenoid |
JP2010235483A (en) * | 2009-03-31 | 2010-10-21 | Kose Corp | Singlet oxygen scavenger and skin external preparation and cosmetic containing the same |
JP2010285364A (en) * | 2009-06-10 | 2010-12-24 | Riken Vitamin Co Ltd | Singlet oxygen scavenger |
WO2011040070A1 (en) * | 2009-09-30 | 2011-04-07 | 株式会社資生堂 | Oral composition for alleviation of ultraviolet radiation-induced damage |
JP5703228B2 (en) * | 2009-09-30 | 2015-04-15 | 株式会社 資生堂 | UV damage reducing oral composition |
JP2011162493A (en) * | 2010-02-12 | 2011-08-25 | Riken Vitamin Co Ltd | Crocetin composition |
JP2013126965A (en) * | 2011-11-14 | 2013-06-27 | Fujifilm Corp | Nrf2 ACTIVATOR FOR NORMAL SKIN CELL |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH05320036A (en) | Composition for eliminating singlet oxygen | |
CN1838935B (en) | Agent for eliminating singlet oxygen and composition using the same | |
EP1742710B1 (en) | Stabilized ascorbic acid compositions and methods therefor | |
JPH11193226A (en) | Collagen crosslink suppressant | |
JP4043942B2 (en) | Stabilized ascorbic acid solution; its use; method for its preparation; and formulations containing it | |
AU744584B2 (en) | Stable liquid mineral ascorbate compositions and methods of manufacture and use | |
JPH107541A (en) | Skin lotion | |
CN114617780A (en) | Retinol derivative oily gel beads, skin care composition containing oily gel beads and preparation method | |
CN107496181A (en) | Solubilizing systems containing resveratrol | |
JP2822093B2 (en) | W / O / W type emulsified cosmetic | |
JP2676049B2 (en) | Skin cosmetics | |
JP2799569B2 (en) | Antioxidant composition | |
JPH0797322A (en) | Singlet oxygen elimination agent | |
JPH05201847A (en) | Skin-beautifying cosmetic | |
JPH08301745A (en) | Skin cosmetic | |
JP2799568B2 (en) | Antioxidant composition | |
JP4285939B2 (en) | Topical skin preparation | |
JPH01135887A (en) | Ultraviolet ray absorber composition | |
KR20210158214A (en) | Ascorbyl Tetraisopalmitate-solubilization ferrocene nanocapsule composition having improved stability, and method for preparing the same, and cosmetic composition containing the same | |
EP0445735A1 (en) | Melanogenesis-inhibiting endermic preparation | |
JPS63254181A (en) | Antioxidant composition | |
JPH11180854A (en) | Skin preparation for external use | |
KR102696921B1 (en) | Nanoparticles that encapsulated with isoflavone, preparation method thereof and cosmetic composition for anti-wrinkles or skin aging prevention | |
JPH0873311A (en) | External preparation for skin | |
KR101457182B1 (en) | emulsion powder cosmetic composition in solid-in-oil containing water soluble ingredient, and method for manufacturing the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A300 | Withdrawal of application because of no request for examination |
Free format text: JAPANESE INTERMEDIATE CODE: A300 Effective date: 19990803 |